Módulo 3 – Curso pós-graduado – VIH e Envelhecimento

Neurocognitive Disorders in HIV Infected Patients

Epidemiologia das alterações neurocognitivas nos doentes infetados por VIH


  1. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV associated neurocognitive disorders. Neurology 2007, 69:1789-99.
  2. EACS Guidelines version 8.0 October 2015 [cancer screening guidelines] (available in http://www.eacsociety.org/files/guidelines_8_0-english_web.pdf, accessed 20 December 2016)
  3. Wright E, Brew B, Arayawichanont A, et al. Neurologic disorders are prevalent in HIV-positive outpatients in the Asia-Pacific region. Neurology. 2008;71:50-6.
  4. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24:1243-50.
  5. Robertson KR, Smurzynski M, Parsons TD, et The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007;21:1915-21.
  6. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Neurology. 2010;75: 2087-96.
  7. Yusuf AJ, Hassan A, Mamman AI, Muktar HM, Suleiman AM, Baiyewu O. Prevalence of HIV-Associated Neurocognitive Disorder (HAND) among Patients Attending a Tertiary Health Facility in Northern Nigeria. J Int Assoc Provid AIDS Care. pii: 2325957414553839.
  8. Pinnetti C, Libertone R, Balestra P, et Declining Prevalence of HIV-Associated Neurocognitive Disorders in More Recent Years. CROI February 23-26, 2015. Seattle [abstract #63]
  9. Focà E, Magro P, Motta D, et al. Screening for Neurocognitive Impairment in HIV-Infected Individuals at First Contact after HIV Diagnosis: The Experience of a Large Clinical Center in Northern Italy. Int J Mol Sci. 2016;17:434.
  10. Heaton RK, Grant I, Butters N, et al. The HNRC 500–neuropsychology of HIV infection at different disease HIV Neurobehavioral Research Center. J Int Neuropsychol Soc. 1995;1:231-51.
  11. Saylor D, Dickens AM, Sacktor N, et al. HIV-associated neurocognitive disorder–pathogenesis and prospects for Nat Rev Neurol. 2016;12:234-48.
  12. Nightingale S, Winston A, Letendre S, et Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014;13:1139-51.
  13. Justin C. McArthur. CROI 2011 presentation
  14. Sacktor N, Skolasky RL, Seaberg E, et al. Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Neurology. 2016;86:334-40.
  15. Cole MA, Margolick JB, Cox C, et al. Longitudinally preserved psychomotor performance in long-term asymptomatic HIV-infected individuals. Neurology. 2007;69:2213-20.
  16. Heaton RK, Franklin DR Jr, Deutsch R, et al. Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER Clin Infect Dis. 2015;60:473-80.
  17. Grant I, Franklin DR Jr, Deutsch R, et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014;82:2055-62.
  18. Rourke S et al. Relative Risk and Factors Associated With Progression to Symptomatic CROI, February 23-26, 2015, Seattle, Washington. Po#465
  19. Vivithanaporn P, Heo G, Gamble J, et al. Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based Neurology. 2010;75:1150-8.
  20. Sevigny JJ, Albert SM, McDermott MP, et al. An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol. 2007;64:97-102.
  21. Heaton RK, Marcotte TD, Mindt MR, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc. 2004;10:317-31.
  22. Heaton RK, Velin RA, McCutchan JA, et al. Neuropsychological impairment in human immunodeficiency virus-infection: implications for employment. HNRC Group. HIV Neurobehavioral Research Psychosom Med. 1994;56:8-17.
  23. Woods SP, Moran LM, Carey CL, et al. Prospective memory in HIV infection: is “remembering to remember” a unique predictor of self-reported medication management? Arch Clin Neuropsychol. 2008;23:257-70.
  24. Hinkin CH, Castellon SA, Durvasula RS, et Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology. 2002;59:1944-50.
  25. Marcotte TD, Lazzaretto D, Scott JC, et Visual attention deficits are associated with driving accidents in cognitively-impaired HIV-infected individuals. J Clin Exp Neuropsychol. 2006;28:13-28.
  26. Nightingale S, Winston A, Letendre S, et Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014;13:1139-51.
  27. Levy HIV-associated neurocognitive disorders: still a hot topic? Isr Med Assoc J. 2015;17:52-3.
  28. Clifford DB, Ances BM. HIV-associated neurocognitive disorder. Lancet Infect Dis. 2013;13:976-86.
  29. Tedaldi EM, Minniti NL, Fischer HIV-associated neurocognitive disorders: the relationship of HIV infection with physical and social comorbidities. Biomed Res Int. 2015;2015:641913.
  30. Mind Exchange Working Group. Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Clin Infect Dis. 2013;56:1004-17.
Logo MSD Termos de utilização | Política de Privacidade | Sobre a MSD Copyright © 2018 Todos os direitos reservados. Merck Sharp & Dohme Corp.,uma subsidiária da Merck & Co., Inc. Kenilworth, NJ, USA, conhecida fora dos EUA e Canadá como MSD. Os conteúdos disponibilizados nesta página Web são informação de carácter geral e não substituem em nenhum caso as consultas, tratamentos ou as recomendações do seu médico. INFC-1273571-0000 11/2018